CrossAssetDataThe Company File
···
AZTA

Azenta, Inc.

Azenta, Inc. is classed by the SEC under Special Industry Machinery, NEC (industry code 3559), based in Burlington, MA. In its latest annual figures on file, for the fiscal year ended 2025-09-30, it reported revenue of $594 million and a loss of $56 million (its filed statements).

Product business Special Industry Machinery, NEC Burlington, MA filings since 1996 9 of 9 filed
Ask the desk about AZTA → Compare AZTA with ACMR → Price chart on TradingView ↗ Full EDGAR file ↗ Watch AZTA →

Sector peers: ACMRACLSVECOCRCT

4.3/10headline grade
vs its business-model standard
5.0/10past 4.1/10present 4.0/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3559, Special Industry Machinery, NEC); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 4.3 out of ten, 9 of 9 metrics filed: past 5.0 out of ten, present 4.1 out of ten, future 4.0 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 4.6 out of ten. 3 warning events since 2017; the latest 2025-12-02. 46th percentile among 13 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 3.3 out of ten. +1.5% a year over 9 filed years; profitable in 6 of 9. 33rd percentile among 13 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 9.0 out of ten. Share count shrank 15.1% a year. 100% of cash flow returned. Insiders: 0 sales, 2 purchases. 90th percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 5.4 out of ten. ROE -3%: lost 3¢ per shareholder dollar. Leverage 16%: owes 16¢ per asset dollar. 54th percentile among 13 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 4.1 out of ten. bottom 41% of 13 in its family; net margin -9.4%. 41st percentile among 13 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 1.5 out of ten. bottom 15% of 12 in its family for leadership; chief executive since 2026. 15th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 3.5 out of ten. bottom 35% of 13 in its family for room to expand. 35th percentile among 13 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 5.5 out of ten. top 45% of 13 in its family for growth drivers. 55th percentile among 13 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 2.7 out of ten. bottom 27% of 13 in its family for expectations against reality. 27th percentile among 13 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2025-12-04 for the period ended 2025-09-30 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-04 (on EDGAR). Newest filing: Form 8-K, 2026-10-07. Filings on record since 1996. Read from EDGAR 2026-10-12.

Where the revenue comes from

Lines of business in fiscal 2025: Multiomics 45%, Core Products 33%, Sample Repository Solutions 21%. By geography: United States 62%, Europe 18%, China 10%, United Kingdom 6%, Asia Pacific 4%, Other 1%. As tagged in its annual report (Form 10-K, filed 2025-12-04).

Who runs it

Madaus, Martin D (Interim CEO); Marotta, John (President and CEO); Martin, William E. III (President Multiomics); Lin, Lawrence Y. (EVP, CFO and Treasurer); Bello, Erik J. (VP Chief Accounting Officer); Pirogova, Olga (SVP and CHRO); Starr, Ephraim (SVP, Gen Counsel & Secretary); Zhou, Ginger (SVP and GM, Multiomics); Cornog, William L (director); Koffey, Quentin (director); and 6 more. 16 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.